SESSION TITLE: COPD Biomarkers
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Monday, October 27, 2014 at 07:30 AM - 08:30 AM
PURPOSE: Pulmonary and activation-regulated chemokine (PARC)/CC-chemokine ligand-18(CCL-18) is mainly expressed by the antigen presenting cells in lungs.Serum CCL-18 levels were found to be elevated in COPD patients. We aimed to study if serum CCL-18 level can differentiate the frequent exacerbator phenotype of COPD from the infrequent exacerbators.
METHODS: This case-control study was conducted in a tertiary reference center in Turkey.Clinically stable COPD patients and HCs were enrolled.Subjects willing to participate underwent a questionnaire including disease characteristics. Severity of dyspnea and symptoms were assessed by the modified Medical Research Council (mMRC) Dyspnea Scale, and COPD Assessment Test (CAT).Spirometry and six-minute walking test (6MWT) were performed.Serum CCL-18 levels were measured with a commercial ELISA Kit.
RESULTS: Sixty COPD patients and 29 HCs were recruited (mean age:58.4±15.5 years old). COPD patients were grouped as frequent exacerbators (FE-COPD,n=33) and infrequent exacerbators (IE-COPD,n=27) based on exacerbation frequency (≥2/year vs.<2/year). CCL18 levels were elevated in COPD patients when compared with the HCs (p=0.0001).CCL18 values did not differ significantly among IE-COPD and FE-COPD groups, though there was an increasing trend between these groups (p=0.09). The number of COPD exacerbations were associated with the serum CCL-18 levels (r=0.30,p=0.026). Serum CCL-18 levels were inversely correlated with the postbronchodilatorFEV1/FVC, postbronchodilatorFEV1%predicted, and the postbronchodilatorFVC %predicted (r=-0.36,p=0.002;r=-0.42,p=0.001and r= -0.47,p<0.0001,respectively). Elevated serum CCL-18 levels were associated with higher mMRC and CAT scores (r=0.46,p<0.0001;r=0.40,p<0.0001,respectively).Decreased exercise capacity as measured by 6MWD was inversely related with serum CCL-18 levels (r=-0.29, p=0.02.
CONCLUSIONS: We have shown that serum PARC/CCL-18 levels are elavated in COPD patients. Although we observed an increasing trend in CCL-18 levels between IE-COPD and FE-COPD groups, the difference was not significant. Nevertheless, a moderate correlation between frequency of COPD exacerbations and serum CCL-18 level were observed. Further studies are needed to explore these results
CLINICAL IMPLICATIONS: PARC/CCL-18 could be a useful biomarker in COPD, since it is associated with frequency of exacerbations in addition to functional parameters and symptom scores.
DISCLOSURE: The following authors have nothing to disclose: Asli Gorek Dilektasli, Ezgi Demirdogen Cetinoglu, Esra Uzaslan, Ferah Budak, Funda Coskun, Ahmet Ursavas, Ercument Ege
No Product/Research Disclosure Information